+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-VEGF Therapy for Cancer Market - Global Forecast 2026-2032- Product Image
Anti-VEGF Therapy for Cancer Market - Global Forecast 2026-2032- Product Image
Sale

Anti-VEGF Therapy for Cancer Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6147784
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-VEGF Therapy for Cancer Market is projected to reach USD 14.02 Billion in 2026. It is expected to continue growing at a CAGR of 4.94%, reaching USD 18.68 Billion by 2032.

Anti-VEGF Therapy for Cancer: Executive Overview

Anti-VEGF therapy for cancer inhibits vascular endothelial growth factor signaling to restrict tumor-associated blood-vessel formation. It is used across several oncology settings, often alongside chemotherapy, immunotherapy, radiotherapy, or other targeted treatments. Clinical use depends on tumor type, biomarker evidence, treatment line, patient fitness, and the balance between therapeutic benefit and risks such as hypertension, bleeding, thrombosis, impaired wound healing, and proteinuria.

How Precision Oncology and Combination Care Are Reshaping Treatment

The treatment landscape is shifting from broad anti-angiogenic use toward more selective, evidence-led integration within multimodal care. Companion diagnostics, molecular profiling, real-world evidence, and improved imaging are helping clinicians identify patients more likely to benefit and monitor response or progression. Combination regimens remain important, but their adoption requires careful assessment of toxicity, sequencing, drug interactions, reimbursement, and the practical burden of infusion-based care.

Artificial Intelligence Strengthens Selection, Monitoring, and Discovery

Artificial intelligence is being applied to pathology, radiology, electronic health records, and clinical-trial data to identify response patterns, characterize tumor vasculature, and support risk stratification. These tools may improve the detection of progression and treatment-related complications, but their clinical value depends on representative datasets, external validation, interpretability, cybersecurity, and integration into oncology workflows. AI should complement-not replace-clinician judgment and prospective clinical evidence.

Regional Insights: Uneven Access and Different Evidence Priorities

North America generally combines advanced oncology infrastructure, broad clinical-trial activity, and established regulatory pathways, while access can vary by payer and care setting. Europe emphasizes comparative effectiveness, health-technology assessment, and coordinated safety monitoring, with differences among national reimbursement systems. Asia-Pacific is characterized by expanding oncology capacity, significant patient diversity, and growing investment in precision medicine. Latin America continues to face disparities in diagnostics, specialist access, and medicine funding. The Middle East is strengthening tertiary cancer services and regional referral networks, while Africa faces major constraints in pathology, radiotherapy, specialist staffing, and reliable access to supportive care.

Group Insights: Trade, Regulation, and Health-System Capacity Matter

ASEAN markets differ substantially in regulatory maturity, cancer-center capacity, and reimbursement, making localized evidence and distribution planning important. BRICS members combine large and diverse patient populations with varying domestic manufacturing, public-sector procurement, and access conditions. The European Union benefits from shared scientific and regulatory structures but retains national differences in pricing and reimbursement. G7 systems generally support sophisticated research and pharmacovigilance, while facing affordability and budget-impact scrutiny. GCC countries are developing high-capability hospital networks and centralized procurement approaches. NATO members span diverse health systems, so alliance membership does not imply uniform oncology access or treatment practice.

Country Insights: Distinct Clinical and Access Conditions Across Priority Markets

Australia and Canada combine strong clinical standards with geographically uneven access to specialized oncology services. Brazil and Mexico face regional disparities in diagnostics, public provision, and private-sector coverage. China is expanding oncology infrastructure, domestic innovation, and precision-medicine capabilities, while regulatory and reimbursement pathways continue to evolve. India has major specialist centers alongside substantial affordability and rural-access challenges. Japan and South Korea have advanced hospital systems and strong clinical expertise, with distinct reimbursement and treatment-guideline frameworks. France, Germany, Italy, Spain, and the United Kingdom combine mature oncology practice with differing assessment, procurement, and funding mechanisms. Russia’s oncology capacity and access conditions vary across regions and are affected by supply, regulatory, and health-system constraints. The United States has extensive research and specialist capacity, but coverage, affordability, site-of-care, and prior-authorization requirements can influence treatment access.

Priorities for Leaders: Improve Patient Selection, Safety, and Delivery

Industry leaders should align development programs with clearly defined clinical questions, validated biomarkers, and meaningful patient-centered outcomes. Evidence strategies should include diverse populations, comparative studies, long-term safety follow-up, and real-world monitoring of hypertension, bleeding, thrombosis, renal effects, and wound-healing complications. Organizations should strengthen diagnostic partnerships, invest in interoperable data systems, and evaluate AI tools through transparent validation and governance. Access plans should address affordability, cold-chain and infusion requirements where relevant, workforce training, regional referral pathways, and responsible-use education for clinicians and patients.

Research Methodology: Evidence-Based Synthesis of the Treatment Landscape

This executive summary uses a structured review framework focused on the clinical role, treatment combinations, safety considerations, access conditions, technology trends, and health-system implications of anti-VEGF therapy in cancer. Interpretation should be grounded in peer-reviewed clinical studies, regulatory documents, treatment guidelines, pharmacovigilance sources, health-technology assessments, and credible real-world evidence. Regional, group, and country comparisons are qualitative and account for differences in disease burden, infrastructure, reimbursement, regulation, clinical practice, and data availability. No unsupported estimates, forecasts, company-specific claims, or market-sizing assumptions are included.

Conclusion: Evidence-Led Integration Will Define the Next Phase

Anti-VEGF therapy remains an important component of cancer care, but its role is increasingly shaped by precision selection, combination strategies, safety management, and health-system feasibility. Progress will depend on translating biological insight into validated clinical tools, improving equitable access to diagnostics and specialist care, and using digital technologies responsibly. Leaders that connect rigorous evidence generation with practical delivery and patient-centered monitoring will be best positioned to support durable clinical value across diverse oncology settings.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-VEGF Therapy for Cancer Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Lung Cancer
7.5. Ovarian Cancer
7.6. Renal Cell Carcinoma
8. Anti-VEGF Therapy for Cancer Market, by Drug Class
8.1. Introduction
8.2. Monoclonal Antibodies
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Ramucirumab
8.3. Tyrosine Kinase Inhibitors
8.3.1. Pazopanib
8.3.2. Sorafenib
8.3.3. Sunitinib
9. Anti-VEGF Therapy for Cancer Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Maintenance
9.3.1. Bevacizumab Maintenance
9.3.2. Pazopanib Maintenance
9.4. Second Line
9.5. Third Line
10. Anti-VEGF Therapy for Cancer Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.3.1. Capsule
10.3.2. Tablet
10.4. Subcutaneous
11. Anti-VEGF Therapy for Cancer Market, by Distribution Channel
11.1. Introduction
11.2. E-Commerce
11.2.1. Mobile Apps
11.2.2. Web Portals
11.3. Hospital Pharmacies
11.4. Retail Pharmacies
12. Anti-VEGF Therapy for Cancer Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Oncology Centers
12.5. Research Institutes
13. Anti-VEGF Therapy for Cancer Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Anti-VEGF Therapy for Cancer Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Anti-VEGF Therapy for Cancer Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc
17.2. AstraZeneca plc
17.3. Bayer AG
17.4. Biocon Limited
17.5. Bristol-Myers Squibb Company
17.6. Chugai Pharmaceutical Co. Ltd
17.7. Cipla Limited
17.8. Daiichi Sankyo
17.9. Dr. Reddy's Laboratories
17.10. Eisai Co., Ltd.
17.11. Eli Lilly and Company
17.12. Exelixis Inc
17.13. F. Hoffmann-La Roche Ltd
17.14. Innovent Biologics
17.15. Ipsen S.A.
17.16. Johnson & Johnson
17.17. Merck KGaA
17.18. Novartis AG
17.19. Pfizer Inc
17.20. Regeneron Pharmaceuticals Inc
17.21. Sanofi S.A.
17.22. Teva Pharmaceutical Industries Ltd
17.23. Viatris Inc
17.24. Xbrane Biopharma AB
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Anti-VEGF Therapy for Cancer Market, Years Considered for the Study
FIGURE 2. Global Anti-VEGF Therapy for Cancer Market, Research Design
FIGURE 3. Global Anti-VEGF Therapy for Cancer Market, Research Framework
FIGURE 4. Global Anti-VEGF Therapy for Cancer Market, Data Triangulation
FIGURE 5. Global Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2025 vs 2032 (%)
FIGURE 7. Global Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 9. Global Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2025 vs 2032 (%)
FIGURE 11. Global Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 13. Global Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Anti-VEGF Therapy for Cancer Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Anti-VEGF Therapy for Cancer Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Anti-VEGF Therapy for Cancer Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Anti-VEGF Therapy for Cancer Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Anti-VEGF Therapy for Cancer Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Anti-VEGF Therapy for Cancer Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Anti-VEGF Therapy for Cancer Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Anti-VEGF Therapy for Cancer Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Anti-VEGF Therapy for Cancer Market Segmentation & Coverage
TABLE 2. Global Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 3. Global Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 4. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ovarian Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ovarian Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ovarian Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Renal Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Renal Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Renal Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 20. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Aflibercept Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Aflibercept Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Aflibercept Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Bevacizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Bevacizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Bevacizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Ramucirumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Ramucirumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Ramucirumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Tyrosine Kinase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Tyrosine Kinase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Tyrosine Kinase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Pazopanib Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Pazopanib Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Pazopanib Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Sorafenib Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Sorafenib Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Sorafenib Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Sunitinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Sunitinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Sunitinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 45. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Maintenance Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Maintenance Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Maintenance Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Bevacizumab Maintenance Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Bevacizumab Maintenance Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Bevacizumab Maintenance Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Pazopanib Maintenance Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Pazopanib Maintenance Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Pazopanib Maintenance Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 64. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Global E-Commerce Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global E-Commerce Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global E-Commerce Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Mobile Apps Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Mobile Apps Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Mobile Apps Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Web Portals Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Web Portals Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Web Portals Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Oncology Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Oncology Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Oncology Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Anti-VEGF Therapy for Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. North America Anti-VEGF Therapy for Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. North America Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 123. North America Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 124. North America Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 125. North America Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 126. North America Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 127. North America Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 128. North America Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 129. North America Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 130. North America Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. North America Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 132. North America Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Latin America Anti-VEGF Therapy for Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Latin America Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 135. Latin America Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 136. Latin America Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 137. Latin America Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 138. Latin America Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 139. Latin America Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 140. Latin America Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 141. Latin America Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 142. Latin America Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. Latin America Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 144. Latin America Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Europe Anti-VEGF Therapy for Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Europe Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 147. Europe Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 148. Europe Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 149. Europe Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 150. Europe Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 151. Europe Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 152. Europe Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 153. Europe Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 154. Europe Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. Europe Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 156. Europe Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Middle East Anti-VEGF Therapy for Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Middle East Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 159. Middle East Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 160. Middle East Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 161. Middle East Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 162. Middle East Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 163. Middle East Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 164. Middle East Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 165. Middle East Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 166. Middle East Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Middle East Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 168. Middle East Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Africa Anti-VEGF Therapy for Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Africa Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 171. Africa Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 172. Africa Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 173. Africa Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 174. Africa Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 175. Africa Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 176. Africa Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 177. Africa Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 178. Africa Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 179. Africa Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 180. Africa Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Global Anti-VEGF Therapy for Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 184. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 185. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 186. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 187. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 188. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 189. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 190. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 191. ASEAN Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. ASEAN Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 193. ASEAN Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. GCC Anti-VEGF Therapy for Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. GCC Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 196. GCC Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 197. GCC Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 198. GCC Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 199. GCC Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 200. GCC Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 201. GCC Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 202. GCC Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 203. GCC Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. GCC Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 205. GCC Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. European Union Anti-VEGF Therapy for Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. European Union Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 208. European Union Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 209. European Union Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 210. European Union Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 211. European Union Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 212. European Union Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 213. European Union Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 214. European Union Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 215. European Union Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. European Union Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 217. European Union Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. BRICS Anti-VEGF Therapy for Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. BRICS Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 220. BRICS Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 221. BRICS Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 222. BRICS Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 223. BRICS Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 224. BRICS Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 225. BRICS Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 226. BRICS Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 227. BRICS Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. BRICS Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 229. BRICS Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. G7 Anti-VEGF Therapy for Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. G7 Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 232. G7 Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 233. G7 Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 234. G7 Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 235. G7 Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 236. G7 Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 237. G7 Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 238. G7 Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 239. G7 Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. G7 Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 241. G7 Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. NATO Anti-VEGF Therapy for Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. NATO Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 244. NATO Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 245. NATO Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 246. NATO Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 247. NATO Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 248. NATO Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 249. NATO Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 250. NATO Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 251. NATO Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. NATO Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 253. NATO Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. Global Anti-VEGF Therapy for Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 255. United States Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 256. United States Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 257. United States Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 258. United States Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 259. United States Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 260. United States Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 261. United States Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 262. United States Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 263. United States Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 264. United States Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 265. United States Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 266. United States Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. Canada Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 268. Canada Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 269. Canada Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 270. Canada Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 271. Canada Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 272. Canada Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 273. Canada Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 274. Canada Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 275. Canada Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 276. Canada Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Canada Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 278. Canada Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 279. Mexico Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 280. Mexico Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 281. Mexico Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 282. Mexico Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 283. Mexico Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 284. Mexico Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 285. Mexico Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 286. Mexico Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 287. Mexico Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 288. Mexico Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 289. Mexico Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 290. Mexico Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 291. Brazil Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 292. Brazil Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 293. Brazil Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 294. Brazil Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 295. Brazil Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 296. Brazil Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 297. Brazil Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 298. Brazil Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 299. Brazil Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 300. Brazil Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 301. Brazil Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 302. Brazil Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 303. United Kingdom Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 304. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 305. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 306. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 307. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 308. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 309. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 310. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 311. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 312. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 314. United Kingdom Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 315. Germany Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 316. Germany Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 317. Germany Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 318. Germany Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 319. Germany Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 320. Germany Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 321. Germany Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 322. Germany Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 323. Germany Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 324. Germany Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 325. Germany Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 326. Germany Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. France Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 328. France Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 329. France Anti-VEGF Therapy for Cancer Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 330. France Anti-VEGF Therapy for Cancer Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 331. France Anti-VEGF Therapy for Cancer Market Size, by Tyrosine Kinase Inhibitors, 2017-2032 (USD Million)
TABLE 332. France Anti-VEGF Therapy for Cancer Market Size, by Therapy Line, 2017-2032 (USD Million)
TABLE 333. France Anti-VEGF Therapy for Cancer Market Size, by Maintenance, 2017-2032 (USD Million)
TABLE 334. France Anti-VEGF Therapy for Cancer Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 335. France Anti-VEGF Therapy for Cancer Market Size, by Oral, 2017-2032 (USD Million)
TABLE 336. France Anti-VEGF Therapy for Cancer Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 337. France Anti-VEGF Therapy for Cancer Market Size, by E-Commerce, 2017-2032 (USD Million)
TABLE 338. France Anti-VEGF Therapy for Cancer Market Size, by End User, 2017-2032 (USD Million)
TABLE 339. Russia Anti-VEGF Therapy for Cancer Market Size, 2017-2032 (USD Million)
TABLE 340. Russia Anti-VEGF Therapy for Cancer Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 341. Russia Anti-VEGF

Companies Mentioned

  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co. Ltd
  • Cipla Limited
  • Daiichi Sankyo
  • Dr. Reddy's Laboratories
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Innovent Biologics
  • Ipsen S.A.
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Xbrane Biopharma AB

Related Topics

Related Reports

Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Image

United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • 80 Pages
  • United States
From
North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030 - Product Image

North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

  • Report
  • 151 Pages
  • North America
From
Oncology Drugs Market 2026-2030 - Product Image

Oncology Drugs Market 2026-2030

  • Report
  • 316 Pages
  • Global
From
VEGF Inhibitors for Cancer Market - Global Forecast 2026-2032 - Product Image

VEGF Inhibitors for Cancer Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.